Delavirdine Susceptibilities and Associated Reverse Transcriptase Mutations in Human Immunodeficiency Virus Type 1 Isolates from Patients in a Phase I/II Trial of Delavirdine Monotherapy (ACTG 260)
- 1 March 2000
- journal article
- clinical trial
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 44 (3), 794-797
- https://doi.org/10.1128/aac.44.3.794-797.2000
Abstract
The development of human immunodeficiency virus type 1 resistance to delavirdine (DLV) was studied in subjects receiving DLV monotherapy. Phenotypic resistance developed in 28 of 30 subjects within 8 weeks. K103N and Y181C, which confer nonnucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance, were the predominant reverse transcriptase mutations. P236L, which confers DLV resistance but hypersensitivity to other NNRTIs, developed in <10% of isolates.Keywords
This publication has 14 references indexed in Scilit:
- HIV-1 Drug Susceptibilities and Reverse Transcriptase Mutations in Patients Receiving Combination Therapy with Didanosine and DelavirdineJAIDS Journal of Acquired Immune Deficiency Syndromes, 1997
- L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptaseAntimicrobial Agents and Chemotherapy, 1995
- Mechanism of Inhibition of HIV-1 Reverse Transcriptase by Nonnucleoside InhibitorsScience, 1995
- A Short-Term Clinical Evaluation of L-697,661, a Non-Nucleoside Inhibitor of HIV-1 Reverse TranscriptaseNew England Journal of Medicine, 1993
- Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitorsAntimicrobial Agents and Chemotherapy, 1993
- A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors.Proceedings of the National Academy of Sciences of the United States of America, 1993
- U-90152, a potent inhibitor of human immunodeficiency virus type 1 replicationAntimicrobial Agents and Chemotherapy, 1993
- Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working GroupAntimicrobial Agents and Chemotherapy, 1993
- Crystal Structure at 3.5 Å Resolution of HIV-1 Reverse Transcriptase Complexed with an InhibitorScience, 1992
- Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture.Proceedings of the National Academy of Sciences of the United States of America, 1991